Alimera Sciences to Report Third Quarter 2017 Resu

ATLANTA, Oct. 25, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences (NASDAQ: ALIM ), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the third quarter ended September 30, 2017, after the close of the financial markets on Wednesday, November 1, 2017.

An accompanying conference call will be hosted by Dan Myers, Chief Executive Officer and Rick Eiswirth, President and Chief Financial Officer to discuss the results. The call will be held at 9:00 AM ET, on Thursday, November 2, 2017. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Details Conference date: Thursday, November 2nd, 2017 9:00 AM ET Conference dial-in: 877.269.7756 International dial-in: 201.689.7817 Conference Call Name: Alimera Sciences' Third Quarter 2017 Results Call Webcast Registration: Click Here Following the live call, a replay will be available on the Company's website, www.alimerasciences.com , under "Investor Relations".

About Alimera Sciences Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in Alimera’s product and development portfolio designed to treat early and late stage diseases. For more information, please visit www.alimerasciences.com .

Contact CG CAPITAL Rich Cockrell 877.889.1972 investorrelations@cg.capital